A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201A, An Anti-HER2-Antibody Drug Conjugate, Versus Ado-Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated

Cancer Type

Breast

ClinicalTrials.gov Identifier

ClinicalTrials.gov registration not required

Principal Investigator

Virginia Kaklamani MD

For more information about this study

View Details